ESIP warns against IP extensions in the EU Biotech Act (Press release)
ESIP expresses concern about the intellectual property (IP) provisions included in the European Commission’s proposal for the EU Biotech Act.
"Europe’s competitiveness must not be built on longer monopolies financed by public health systems. The Biotech Act must instead safeguard affordability through biosimilar competition starting on day one after existing IP expires. Extending exclusivities would delay competition, undermine sustainability and ultimately restrict patient access” says Yannis Natsis, ESIP Director.